IRVINE, Calif., July 25, 2019 /PRNewswire/ -- Cryoport, Inc.
(NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport" or "the Company"), the
world's leading temperature-controlled logistics company dedicated
to the life sciences industry, today announced that the Company
will report financial results for the second quarter ended
June 30, 2019 on Thursday, August 8, 2019 after U.S. markets
In addition to the earnings release, a document titled "Cryoport
Second Quarter 2019 in Review", which will provide a review of
Cryoport's recent financial and operational performance and a
general business update, will be issued by management at
4:05 pm ET on Thursday, August 8. The
document is designed to be read by investors before the questions
and answers conference call and can be accessed at
Cryoport management will host a conference call at 5:00 pm ET on August 8,
2019. The conference call will be in the format of a
questions and answers session and will address any queries
investors have regarding the Company's reported results.
Conference Call Information
Thursday, August 8,
+1 (855) 327-6837
(U.S.) or +1 (631) 891-4304 (International)
Call" or provide code 10007349
section at www.cryoport.com or at this link. Please allow 10
minutes prior to the call to visit this site to download and
install any necessary audio software.
An archive of the question and answer webcast will be available
approximately three hours after completion of the live event and
will be accessible on the Investor Relations section of the
Company's website at www.cryoport.com for a limited time. To
access the replay of the webcast, please follow this link. A
dial-in replay of the call will also be available to those
interested until August 15,
2019. To access the replay, dial +1 (844) 512-2921
(United States) or +1 (412)
317-6671 (International) and enter replay pin number: 10007349.
About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted global
provider of temperature-controlled logistics solutions for
temperature-sensitive life sciences commodities, serving the
biopharmaceutical market with leading-edge logistics solutions for
biologic materials, such as regenerative medicine, including
immunotherapies, stem cells and CAR T-cells. Cryoport also provides
a range of bioservices to the life sciences industry, including
biostorage for biological specimens, materials and samples.
Cryoport's solutions are used by points-of-care, CRO's, central
laboratories, pharmaceutical companies, manufacturers, university
researchers et al; as well as the reproductive medicine market,
primarily in IVF and surrogacy; and the animal health market,
primarily in the areas of vaccines and reproduction. Cryoport's
proprietary Cryoport Express® Shippers, Cryoportal® Logistics
Management Platform, leading-edge SmartPak II™ Condition Monitoring
System and geo-sensing technology, paired with unparalleled cold
chain logistics expertise and 24/7 client support, make Cryoport
the end-to-end cold chain logistics partner that the industry
trusts. Cryoport is dedicated to: simplifying global cold chain
logistics through innovative technology, unmatched monitoring and
data capture and support, including consulting; delivering the most
advanced temperature-controlled logistics solutions for the life
sciences industry; and providing vital information that provides
peace of mind throughout the life of each logistics process.
For more information, visit www.cryoport.com. Sign up to
follow @cryoport on
Twitter at www.twitter.com/cryoport.
Forward Looking Statements
Statements in this news release which are not purely historical,
including statements regarding Cryoport, Inc.'s intentions, hopes,
beliefs, expectations, representations, projections, plans or
predictions of the future are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. It
is important to note that the Company's actual results could differ
materially from those in any such forward-looking statements.
Factors that could cause actual results to differ materially
include, but are not limited to, risks and uncertainties associated
with the effect of changing economic conditions, trends in the
products markets, variations in the Company's cash flow, market
acceptance risks, and technical development risks. The Company's
business could be affected by a number of other factors, including
the risk factors listed from time to time in the Company's SEC
reports including, but not limited to, the Company's 10-K for the
year ended December 31, 2018 filed
with the SEC. The Company cautions investors not to place undue
reliance on the forward-looking statements contained in this press
release. Cryoport, Inc. disclaims any obligation, and does not
undertake to update or revise any forward-looking statements in
this press release.
View original content to download
SOURCE Cryoport, Inc.